Metamizol Teva-Ratiopharm (Metamizole Magnesium)

Metamizole works by inhibiting cyclooxygenase enzymes, which reduces the production of prostaglandins. Lower prostaglandin levels diminish peripheral pain signaling and the central fever response, resulting in analgesic and antipyretic effects.

The appropriate dose of Metamizol Teva-Ratiopharm is determined by the prescribing clinician based on the patient’s specific condition, severity of pain, and individual health factors. Dosage regimens are individualized and should follow the prescriber’s instructions.

Safety data for Metamizole during pregnancy and lactation are limited. It should only be used if the potential therapeutic benefit justifies any potential risk to the fetus or infant, and only after consultation with a qualified healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity and providing institutional or trade credentials. GNH India will respond with pricing, availability, shipping details (including any cold‑chain requirements if applicable), and the necessary import documentation.

Compared with traditional NSAIDs, Metamizole provides analgesic and antipyretic effects via a distinct mechanism and may have a lower risk of gastrointestinal irritation. However, it carries a rare but serious risk of agranulocytosis. Choice of therapy should be based on individual patient risk factors and clinical judgment.

Store the product at ambient temperature below 25 °C. Keep it in the original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Metamizol Teva-Ratiopharm is taken orally as directed by a healthcare professional, typically with a glass of water. Tablets or oral solutions should be swallowed whole unless the prescriber provides specific instructions for splitting or crushing.

The most serious adverse reactions include agranulocytosis (a severe drop in white blood cells), life‑threatening skin reactions such as Stevens‑Johnson syndrome, and anaphylactic shock. Patients should be monitored for signs of infection, skin changes, or allergic reactions, and treatment should be stopped immediately if these occur.

Metamizol should be avoided in individuals with known hypersensitivity to Metamizole or other pyrazolones, patients with a history of agranulocytosis, and those with severe hepatic or renal impairment unless a physician determines that the benefits outweigh the risks.